Answers are grounded in this paper and cite their sources.
Case report confirms BCR-ABL's role in determining treatment for acute myeloid leukemia, suggesting enhanced diagnostics.
We present a case report of a patient with acute myeloid leukemia (AML) characterized by the simultaneous presence of nucleophosmin 1 (NPM1) mutation and the breakpoint cluster region-Abelson (BCR-ABL) fusion oncogene. Our findings emphasize the importance of routinely including BCR-ABL in the diagnostic workup of AML in order to offer to the patients the most appropriate risk category and treatment options.
No takes yet. Share an insight, caveat, or question.
Mariotti et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: